Intercellular adhesion molecule 1 antibody-mediated mesoporous drug delivery system for targeted treatment of...

Area of Science:

• Biomedical Engineering
• Nanotechnology
• Oncology

Background:

• Triple-negative breast cancer (TNBC) lacks effective targeted therapies.
• Developing targeted drug delivery systems is crucial for improving cancer treatment efficacy.
• Periodic mesoporous organosilica nanoparticles (PMOs) offer potential for drug delivery applications.

Purpose of the Study:

• To develop and evaluate a targeted drug delivery system for TNBC using engineered PMOs.
• To assess the biocompatibility, drug loading capacity, and release profile of the nanoparticles.
• To investigate the in vitro and in vivo targeting efficiency and therapeutic effects on TNBC.

Main Methods:

• Engineered PMOs with cyanine 5.5 (Cy5.5) and an ICAM-1 antibody (PMO-Cy5.5-ICAM).
• Doxorubicin (DOX) loading into PMO-Cy5.5-ICAM, creating DOX@PMO-Cy5.5-ICAM.
• In vitro studies using confocal microscopy to assess cell targeting and entry.
• In vivo experiments in TNBC models to evaluate drug accumulation and therapeutic efficacy.

Main Results:

• PMO-Cy5.5-ICAM demonstrated excellent in vitro and in vivo biocompatibility.
• The system achieved a high doxorubicin loading capacity (up to 400 mg/g).
• DOX@PMO-Cy5.5-ICAM showed pH-sensitive drug release and efficient targeting and uptake by TNBC cells.
• In vivo studies confirmed enhanced accumulation in TNBCs and superior therapeutic effects compared to controls.

Conclusions:

• The DOX@PMO-Cy5.5-ICAM system is a promising targeted therapy for TNBC.
• This nanoparticle-based approach offers improved biocompatibility and therapeutic efficacy.
• Further development could lead to advanced treatment strategies for triple-negative breast cancer.